MD MBA - Indaptus Therapeutics Chief Officer
| INDP Stock | USD 0.94 0.05 5.62% |
Executive
MD MBA is Chief Officer of Indaptus Therapeutics
| Age | 56 |
| Address | Three Columbus Circle, New York, NY, United States, 10019 |
| Phone | 646 427 2727 |
| Web | https://indaptusrx.com |
Indaptus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7112) % which means that it has lost $0.7112 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2704) %, meaning that it created substantial loss on money invested by shareholders. Indaptus Therapeutics' management efficiency ratios could be used to measure how well Indaptus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/22/2024, Return On Tangible Assets is likely to drop to -1.09. In addition to that, Return On Capital Employed is likely to grow to -1.28. At this time, Indaptus Therapeutics' Total Current Liabilities is relatively stable compared to the past year. As of 12/22/2024, Liabilities And Stockholders Equity is likely to grow to about 23.5 M, while Non Current Liabilities Total is likely to drop slightly above 69.7 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Shannon Ryan | Assembly Biosciences | N/A | |
| Melissa CPA | Kiora Pharmaceuticals | 44 | |
| Richard Colonno | Assembly Biosciences | 74 | |
| James Wang | Virax Biolabs Group | N/A | |
| Lindsay Young | Tempest Therapeutics | N/A | |
| Amy CFA | Assembly Biosciences | N/A | |
| Patrick Ryan | Nutriband | 38 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Daron Evans | Rezolute | 50 | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Anuj MD | Assembly Biosciences | 46 | |
| Lisa Locklear | Longeveron LLC | 63 | |
| Gopal MBBS | Rezolute | N/A | |
| Graeme Currie | Pasithea Therapeutics Corp | 57 | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Uttam Patil | ABVC Biopharma | 38 | |
| Samuel MD | Tempest Therapeutics | 58 | |
| Ryan Witt | RenovoRx | N/A | |
| Clement Monteil | Virax Biolabs Group | N/A | |
| MS MBA | Rezolute | 50 | |
Management Performance
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.71 |
Indaptus Therapeutics Leadership Team
Elected by the shareholders, the Indaptus Therapeutics' board of directors comprises two types of representatives: Indaptus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Indaptus. The board's role is to monitor Indaptus Therapeutics' management team and ensure that shareholders' interests are well served. Indaptus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Indaptus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Jeffrey Meckler, CEO Director | ||
| Nir Sassi, Secretary CFO | ||
| Walt Esq, Chief Officer | ||
| Michael Newman, Chief Founder | ||
| Boyan MD, Chief Officer |
Indaptus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Indaptus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 3.78 M | ||||
| Shares Outstanding | 12.01 M | ||||
| Shares Owned By Insiders | 26.67 % | ||||
| Shares Owned By Institutions | 5.99 % | ||||
| Number Of Shares Shorted | 91.96 K | ||||
| Price To Book | 1.84 X | ||||
| EBITDA | (16.38 M) | ||||
| Net Income | (15.42 M) |
Pair Trading with Indaptus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Indaptus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Indaptus Stock
Moving against Indaptus Stock
| 0.68 | VCYT | Veracyte | PairCorr |
| 0.67 | VCEL | Vericel Corp Ord | PairCorr |
| 0.63 | DRTS | Alpha Tau Medical | PairCorr |
| 0.55 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
| 0.46 | VERA | Vera Therapeutics | PairCorr |
The ability to find closely correlated positions to Indaptus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Indaptus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Indaptus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Indaptus Therapeutics to buy it.
The correlation of Indaptus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Indaptus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Indaptus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Indaptus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.